
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded topical paste containing resorcinol, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
No FDA-approved (NDA or ANDA) product containing resorcinol is listed. Products containing it are filed in the directory as over-the-counter monograph drugs and homeopathic products, in paste, cream, liquid and ointment forms.
Bases for this dose form differ, and the base used decides how USP <795> classifies the preparation for beyond-use dating. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Resorcinol is a keratolytic and antiseptic phenol that compounding pharmacies prepare by prescription in topical creams, lotions, solutions and peel preparations.
Resorcinol is a phenol derivative applied to the skin. It is a keratolytic, meaning it loosens and sheds the hardened outer layer of skin, and at higher concentrations it produces a peeling effect; it also has antiseptic activity. It is not approved as a prescription drug on its own. Under the FDA over-the-counter acne monograph, resorcinol is a permitted active ingredient only in combination with sulfur, and manufactured OTC lotions and gels such as Rezamid (sulfur and resorcinol lotion) are marketed under that monograph to dry acne pimples. Consumer references also list it for seborrheic dermatitis, eczema, psoriasis, corns, calluses and warts. A prescriber might order compounded resorcinol when a patient needs a strength above the OTC monograph limit, a single-ingredient preparation without sulfur, or a specific cream or solution vehicle. Compounded preparations are not FDA-approved and require a prescription.
Resorcinol has no FDA prescription label and no boxed warning; the OTC monograph requires labels to say "for external use only," to warn against use on broken skin or large areas, to advise rinsing the eyes with water if contact occurs, and to stop use and ask a doctor if irritation occurs or worsens. Redness and peeling are expected. Resorcinol is absorbed through the skin, especially through wounds or over large areas; poisoning can cause nausea, vomiting, diarrhea, dizziness, drowsiness, headache, slow heartbeat, shortness of breath and sweating, and in infants and children it can cause methemoglobinemia, so it should not be used on large areas of a child's body. It is the peeling agent most often linked to allergic contact reactions and can discolor hair, skin and clothing. Do not layer it with other peeling or acne products unless your prescriber directs. One HS review advises avoiding it in pregnancy for lack of data; e-lactancia rates it probably compatible with breastfeeding but says to keep it off the breast. For side effects, talk to your prescriber or pharmacist.
Resorcinol (1,3-dihydroxybenzene) is a phenolic keratolytic and antiseptic; in hidradenitis suppurativa it is hypothesized to act on the follicular keratin plug, reducing follicular occlusion (Deckers and Prens, 2016). Percutaneous absorption is low, about 1.6% of an applied dose reaching plasma, with a reported half-life of about 14 hours (e-lactancia, citing Yeung 1983). There is no FDA-approved prescription product; the only labeled use is the OTC acne monograph (21 CFR 333.310 and 333.320), where resorcinol or resorcinol monoacetate is permitted solely in combination with sulfur, with Rezamid as a marketed example. Prescribers have ordered compounded higher-strength topical resorcinol for mild hidradenitis suppurativa (Hurley stage I and II), a use described in a 12-patient series and a 61-patient study (Deckers and Prens, 2016; Billewicz et al., 2024), and for chemical peeling (J Eur Acad Dermatol Venereol, 1999 review), all off-label. Strength, vehicle and application area are per prescriber. Counsel on limited application area to reduce systemic absorption, and monitor for contact sensitization, discoloration, and in pediatric patients signs of methemoglobinemia. e-lactancia notes a possible thyroid effect, citing a 2023 toxicology source; the other sources listed here do not describe this effect. Resorcinol is not a controlled substance.
Wash your hands. Apply a layer of paste to clean, dry skin as your label directs, spreading it only over the affected area. Pastes are not meant to be rubbed in. Do not apply to broken skin unless told to. Wash your hands afterward and follow your label for how often to reapply and how to remove it.
Many pastes are nonaqueous and may carry a USP <795> default beyond-use date of up to 180 days; water-containing pastes are limited to 35 days preserved or 14 days refrigerated unpreserved. Keep the container closed at room temperature, out of reach of children, and discard after the beyond-use date on your label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Apply topically to affected area(s)